Verisante Technology, Inc. announced it has initiated communications with the Food and Drug Administration (FDA) in the United States for the approval of Aura, a device for the detection of skin cancer. Verisante has now submitted documents to the FDA as it begins the formal application process for approval to market and sell Aura in the United States.